Background
==========

Myasthenia gravis (MG), a T cell-dependent autoimmune disease, is mediated by specific autoantibodies at the neuromuscular junction (NMJ) and results in distinctive fatigability and limb weakness \[[@b1-medscimonit-26-e919150],[@b2-medscimonit-26-e919150]\]. Experimental autoimmune myasthenia gravis (EAMG) is used as a common model of MG, in which female Lewis rats are immunized with AChR R97-116 peptide \[[@b3-medscimonit-26-e919150],[@b4-medscimonit-26-e919150]\]. After immunization, EAMG animals closely mimic the clinical symptoms, anti-acetylcholine receptors (AChR) antibodies, electrophysiological signs, and immunological parameters of human MG, suggesting that the Lewis rat model is suitable for investigating novel therapeutic avenues in MG. MG also is a chronic inflammatory autoimmune disease. It has been traditionally believed that a highly ordered immune system depends on the balance between anti-inflammatory and pro-inflammatory signals \[[@b5-medscimonit-26-e919150]\]. Many studies in recent years have demonstrated that MG patients have significantly increased expression of pro-inflammatory mediators, including IL-6, TNF-α, interferon (IFN)-γ, and IL-1β \[[@b5-medscimonit-26-e919150],[@b6-medscimonit-26-e919150]\]. At present, the main treatments of MG consist of corticosteroids and immunosuppressants, plasma-exchange, and intravenous immunoglobulin for short-term immunomodulation \[[@b7-medscimonit-26-e919150]\]. However, these treatments often have serious adverse effects due to their inhibition of immunity. Therefore, there is an urgent need for more effective agents with fewer adverse effects to treat MG. Thus, we focused on Traditional Chinese Medicine (TCM) and observed the benefits and mechanisms in the treatment of EAMG Lewis rats.

Nux vomica, the seed of *Strychnos nux vomica L*, is characterized in TCM as being bitter and warm in nature and belongs to the liver and spleen meridians based on the theory of TCM. Additionally, brucine and strychnine are identified as the central toxic and principal bioactive compounds, respectively \[[@b8-medscimonit-26-e919150]\]. Studies have suggested that nux vomica strengthens the central nervous systems \[[@b8-medscimonit-26-e919150],[@b9-medscimonit-26-e919150]\] and possesses analgesic, anti-inflammatory \[[@b10-medscimonit-26-e919150]\], and anti-tumor properties \[[@b8-medscimonit-26-e919150]\]. Furthermore, modern experimental research has demonstrated its immunomodulatory effects. Zou et al. reported that GNV decreased acetylcholine receptor antibody (AChR-ab) levels in EAMG rats \[[@b11-medscimonit-26-e919150]\]. These studies demonstrated the possible clinical value of nux vomica in treatment of autoimmune diseases. The exact anti-inflammatory molecular mechanisms of nux vomica are still largely unknown, and many studies suggest that its anti-inflammatory effect is correlated reduced release of pro-inflammatory cytokines in adjuvants-induced arthritis rats \[[@b12-medscimonit-26-e919150]\].

So far, there is no report about the effect of nux vomica on inflammation under EAMG. In this research, we hypothesized that GNV has a therapeutic effect on EAMG, and aimed to preliminarily assess the potential therapeutic targets and underlying mechanism of GNV capsules on the pathogenesis of EAMG by use of RNA expression profiling.

Material and Methods
====================

Animals
-------

Sixty Lewis rats (6 weeks old, 120--138 g) were used in this study. The rats were obtained from Beijing Vital River Laboratories (Beijing, China; license number: SCXK (Beijing) 2012-0001). All rats were housed in the Animal Center of Zhejiang Chinese Medicine University with a 12-h light/12-h dark cycle, and had free access to standard rat chow and water. All animal experiments were approved by the Animal Care and Welfare Committee of Zhejiang Chinese Medical University (permit number: ZSLL-2019-92, Zhejiang, China). Animal suffering was kept to a minimum, and tissues were harvested after euthanasia by chloral hydrate (TCI Chemical Industrial Development Co., Shanghai, China).

Induction of EAMG and clinical evaluation
-----------------------------------------

The EAMG model was prepared based on previously described methods \[[@b13-medscimonit-26-e919150]\]. We subcutaneously injected 52 rats with 100 μg/200 μL Rat 97-116 peptides (DGDFAIVKFTKVLLDYTGHI, CL Bio-Science Co., Xian, China) in Complete Freund's adjuvant (CFA, Sigma) in the waist, abdomen and hind-foot pads, and boosted with 50 μg Rat 97--116 peptides in 200 μl of incomplete Freund's adjuvant (IFA, Sigma) on days 30 and 45, respectively. The control rats were injected with CFA emulsified in PBS and boosted with IFA in PBS at the same sites. According to the EAMG clinical scale score in a rat model proposed by Lennon et al. \[[@b14-medscimonit-26-e919150]\], clinical evaluation was scored as follows: 0, no fatigue and normal strength; 1, slightly impaired activity, fatigable, and weak grip; 2, weakness, tremor, head down, hunched posture presented before clinical signs; 3, severe weakness, no grip moribund; and 4, death. We used 0.5 increments as intermediate scores assigned to rats with intermediate signs. Lennon scores are presented as the average value of each group at modeling time point.

Nux vomica preparation and animal treatment
-------------------------------------------

Nux vomica (lot no. 170518) was prepared by removing extraneous material, soaking, stir-frying, drying, powdering, and disinfecting at Zhejiang Provincial Hospital of TCM, and each capsule contained 0.2 g of grilled nux vomica. The 40 EAMG rats were split into 5 groups (n=8): a model group, a low-dose group, a middle-dose group, a high-dose group, and a prednisone group (the positive group). EAMG rats received intragastric administration of 75 mg/kg (low-dose group), 150 mg/kg (middle-dose group), and 225 mg/kg (high-dose group) GNV and 4 mg/kg prednisone dissolved in 0.2% sodium carboxymethylcellulose (CMC-Na) solution once a day for 4 weeks. The control and model groups (n=8) received the same volume of CMC-Na solution. After the last immunization and treatment, the parameters of holding power and Lennon scores were recorded. Animal weights were measured every week during treatment.

Repetitive nerve stimulation (RNS) test
---------------------------------------

All animals were fixed on the BL-420S system under anesthesia with 10% chloral hydrate (intraperitoneal). Then, a stimulating electrode was inserted into the gastrocnemius muscle near the sciatic nerve. Subsequently, a reference electrode was inserted into abdominal subcutaneous tissue. In addition, 2 recording electrodes were inserted into the subcutaneous tissue. All the electrodes received a 5 Hz electrical stimulus 10 times. The attenuation value of RNS (D)=(first responses minus the fifth responses)/first responses×100%.

ELISA
-----

After treatment, heart blood was rapidly collected from sacrificed rats, then the blood centrifuged at 3000 rpm for 20 min at 4°C to prepare serum samples. Concentrations of serum AChR-ab, IFN-γ, TNF-α, IL-2, IL-4, IL-17, and TGF-β1 in individual rats were detected by ELISA kit (Nanjing SenBeiJia Bio-Technology Co., Nanjing, China) according to the manufacturer's instructions.

RNA sequencing
--------------

The gastrocnemius muscle was harvested from rats in the model and high-dose groups for subsequent array analysis. The RNA sequencing was conducted at LC-Bio Co. (Hangzhou, China). In brief, total RNA of gastrocnemius muscle tissue specimens was extracted with Trizol solution (Invitrogen, CA, USA) based on the manufacturer's operating instructions. The purity and quantity of total RNA were estimated using the Bioanalyzer device (Agilent, USA) with the RNA integrity number \>7.0. Poly(A) RNA was purified from the total RNA (5 μg) using poly-T oligo-attached magnetic beads with 2 rounds of purification. After purification, the messenger RNA was cut into small pieces with divalent cations at increasing temperatures. The complementary DNA (cDNA) library was subsequently constructed using reverse transcription with the cleaved fragments of RNA according to the protocol of the RNA-Seq sample preparation kit (Illumina, San Diego, USA), and the average insert size for the paired-end libraries was 300±50 bp. Then, we conducted the sequencing on an IlluminaHiseq4000 platform (LC Sciences, USA).

RNA sequencing data and bioinformatics analysis
-----------------------------------------------

We aligned reads of the model and high-dose group samples to the UCSC (*<http://genome.ucsc.edu/>*) \[[@b15-medscimonit-26-e919150]\] rats' reference genome by using the R package of HISAT. The mapped reads of each sample were assembled using StringTie. Then, all transcriptomes from gastrocnemius muscle samples were integrated to reconstruct a complete transcriptome using Perl scripts. Finally, StringTie and edgeR were employed to estimate the expression levels of all transcripts. The DEGs were identified with log~2~ (Fold change, FC) \>1 or log2 (FC) \<−1 with significant difference (p value \<0.05) by R package. The data were visualized with a hierarchical cluster analysis by using GeneSpring (version 7.2) software (Silicon Genetics, CA). The annotation of upregulated/downregulated DEGs was done according to the Metascape database (*<http://metascape.org/>*) \[[@b16-medscimonit-26-e919150]\], a gene annotation and analysis resource. Furthermore, the STRING database (*<http://string-db.org/>*) \[[@b17-medscimonit-26-e919150]\] was used to construct the protein--protein interaction (PPI) networks of up-/downregulated DEGs with combined score \>0.4 as the cut-off criterion, and then visualized with Cytoscape (Version 3.6.1; *<http://cytoscape.org/>*) software. The DEGs act as nodes in the PPI network, and the degree value represents the number of interacting proteins. A node with a higher degree is considered to be the hub node. By analyzing the degree value of the nodes in the PPI up-/downregulated networks, respectively, the hub genes were acquired.

Quantitative real-time PCR
--------------------------

Total RNA was extracted from the same gastrocnemius muscle samples as in the microarray research, using Trizol reagent (Sigma, St. Louis, MO, USA) according to the manufacturer's protocol. The extracted RNA was reverse-transcribed to cDNA with the PrimeScript RT Master Mix (TaKaRa). Then, the real-time PCR was conducted using a TaqMan Universal Master Mix II kit on an Applied Biosystems 7500 Sequence Detection System (Applied Biosystem). The primers for Rac family small GTPase 2 (Rac2), integrin subunit beta 2 (Itgb2), lymphocyte cytosolic protein 2 (Lcp2), myosin light chain 3 (Myl3), and troponin I1, slow skeletal type (Tnni1) are as shown in [Table 1](#t1-medscimonit-26-e919150){ref-type="table"}. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was selected as the internal standard control. The relative mRNA expression levels for hub genes were determined by using the Ct (2^−ΔΔCt^) method.

Western blot assay
------------------

The gastrocnemius muscle tissues were lysed using ice-cold RIPA lysis buffer (Beyotime Biotech, Shanghai, China) supplemented with 1% phenylmethylsulfonyl fluoride (PMSF), and then centrifuged at 12 000 rpm for 15 min at 4°C. Then, the protein concentration was quantified using a bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, USA). We used primary antibodies against Rac2 (\#ab154711, 1: 2000; Abcam, Cambridge, MA), Itgb2 (\#73663, 1: 1000; Cell Signaling), Lcp2 (\#4958, 1: 1000; Cell Signaling), Myl3 (\#ab680, 1: 100; Abcam, Cambridge, MA), Tnni1 (\#ab231720, 1: 2000; Abcam, Cambridge, MA), Toll-like receptor 4 (TLR-4, \#14358, 1: 1000; Cell Signaling), and NF-κB p65 (\#8242, 1: 1000; Cell Signaling), followed by incubating with the secondary antibody against IgG (\#ab7090 or \#ab205719, 1: 5000, Abcam, Cambridge, USA). Protein levels were normalized by probing the same blots with a GAPDH antibody (\#3683, 1: 1,000; Cell Signaling). Finally, the protein bands were visualized with an Odyssey^®^ IR scanner (LI-COR, USA) and quantified by Image J (version 1.8.0) software (National Institutes of Health, NY).

Statistical analysis
--------------------

All data are presented as mean±SD. Data on statistical comparisons between the 2 groups were evaluated with *t* test. P value \<0.05 was defined as a statistically significant difference. SPSS v21.0 (IBM Corp, USA) and GraphPad Prism v5.0 software (San Diego, California, USA) were used for statistical analyses.

Results
=======

GNV capsules ameliorate EAMG symptoms
-------------------------------------

After modeling, the weakness symptoms of EAMG Lewis rats became more obvious, including a humped back, an obvious tremor, and significantly decreased activity. There were statistically significant differences in holding power ([Figure 1A](#f1-medscimonit-26-e919150){ref-type="fig"}, *P*\<0.01) and Lennon scores ([Figure 1B](#f1-medscimonit-26-e919150){ref-type="fig"}, *P*\<0.01) and a decrease in RNS ([Figure 1C](#f1-medscimonit-26-e919150){ref-type="fig"}, *P*\<0.01) when compared to the control group before GNV capsules treatment. Statistical analysis suggested that GNV at 75 mg/kg/day, 150 mg/kg/day, and 225 mg/kg/day decreased the holding power and decreased the clinical Lennon scores for RNS of the treatment groups compared with the model group. Additionally, the effect of GNV on the average body weight was examined weekly during therapy. The average body weight of the model group observably decreased after administration of normal CMC-Na (*P*\<0.01, [Table 2](#t2-medscimonit-26-e919150){ref-type="table"}). GNV and prednisone both reduced the severity of EAMG, and the average body weights of the treatment groups were significantly higher than in the model group (*P*\<0.01). The results showed that GNV has a therapeutic effect on EAMG.

Detection of AChR-ab, TGF-β1, and inflammatory mediators in EAMG
----------------------------------------------------------------

It has been reported that AChR-ab, TGF-β1, and inflammatory mediators are closely related to the process of EAMG; therefore, we used ELISA to estimate the level of AChR-ab, IFN-γ, IL-4, IL-17, TNF-α, IL-2, and TGF-β1 in serum samples. As shown in [Figure 2A--2D](#f2-medscimonit-26-e919150){ref-type="fig"}, the low-dose, middle-dose, and high-dose GNV groups lower levels of AChR-ab, IFN-γ, IL-4, and IL-17 in EAMG rats in comparison with the model group (*P*\<0.01). Similarly, the levels of TNF-α and IL-2 were lower in the middle-dose and high-dose groups than in the model group ([Figure 2E, 2F](#f2-medscimonit-26-e919150){ref-type="fig"}; *P*\<0.01), and there was no significant difference between the low-dose and the model group. Additionally, the TGF-β1 level was clearly higher in the treated groups than in the model group ([Figure 2G](#f2-medscimonit-26-e919150){ref-type="fig"}, *P*\<0.01).

Identification of DEGs and functional enrichment analysis
---------------------------------------------------------

We used the gastrocnemius muscle samples of GNV-treated EAMG rats compared with healthy tissues to select EAMG-associated genes. According to the criteria of *P*\<0.05 and \|logFC\| \>1, 235 DEGs were identified, including 175 upregulated DEGs and 60 downregulated DEGs. Notably, the proportion of upregulated genes was larger than that of downregulated genes in treated groups compared to the model group. The distribution of the 2 groups of DEGs at the logFC and P value levels is shown in [Figure 3A](#f3-medscimonit-26-e919150){ref-type="fig"}. A heat map of hierarchical clustering analysis for the DEGs is shown in [Figure 3B](#f3-medscimonit-26-e919150){ref-type="fig"}, which was created based on the gene expression level and, the results demonstrated a clearly different expression pattern.

To further understand the functional classification of the specific genes, we used the Metascape platform to investigate the biological processes (BP) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of DEGs. The result of GO analysis demonstrated that the upregulated DEGs were most observably enriched in the leukocyte cell--cell adhesion, immune effector, and regulation of the immune response process ([Figure 3C](#f3-medscimonit-26-e919150){ref-type="fig"}). KEGG analysis indicated that the upregulated DEGs were enriched in NF-kappa B signaling pathway and phospholipase D signaling pathway, as well as the disease-related pathway, which include *Staphylococcus aureus* infection, tuberculosis, type I diabetes mellitus, and autoimmune thyroid disease ([Figure 3D](#f3-medscimonit-26-e919150){ref-type="fig"}). Similarly, the downregulated DEGs were mainly enriched in BP terms of muscle contraction and structure development process ([Figure 3E](#f3-medscimonit-26-e919150){ref-type="fig"}). The downregulated DEGs were mainly involved in hypertrophic cardiomyopathy, cardiac muscle contraction, dilated cardiomyopathy, and thyroid hormone signaling pathway ([Figure 3F](#f3-medscimonit-26-e919150){ref-type="fig"}).

PPI network construction and analysis
-------------------------------------

Up-/downregulated DEGs were analyzed by STRING and visualized with Cytoscape, respectively. Ultimately, the PPI network of upregulated DEGs was established with 135 nodes and 746 edges. The proteins Rac2 (degree=53), Itgb2 (degree=46), and Lcp2 (degree=40) were used as hub nodes in the upregulated network ([Figure 4A](#f4-medscimonit-26-e919150){ref-type="fig"}). The PPI network for downregulated DEGs, as shown in [Figure 4B](#f4-medscimonit-26-e919150){ref-type="fig"}, had 23 nodes and 78 edges. The top 2 hub proteins -- Myl3 (degree=16) and Tnni1 (degree=15) -- were selected as hub nodes in this network.

RNA profile validation
----------------------

We performed q-PCR and Western blot analyses to validate the results of RNA profiling. Three upregulated DEGs (Rac2, Itgb2, Lcp2) and 2 downregulated DEGs (Myl3 and Tnni1) were confirmed to be altered across all 4 gastrocnemius muscles samples. The q-PCR and Western blotting results indicated that the mRNA and protein expressions of Rac2, Itgb2, and Lcp2 were significantly higher in the GNV (225 mg/kg)-treated samples compared with that in the model samples ([Figure 5A--5C](#f5-medscimonit-26-e919150){ref-type="fig"}), while the mRNA and protein levels of Myl3 and Tnni1 were lower in GNV-treated samples than in the model samples ([Figure 5D--5F](#f5-medscimonit-26-e919150){ref-type="fig"}). These results were similar to the results acquired using microarray analysis, suggesting that the hub genes from the mRNA microarray analysis were reliable and could be used for further analysis of potential mechanisms.

Effect of GNV on EAMG of TLR-4/NF-κB signaling
----------------------------------------------

Compared with the control group, the model group had higher TLR-4 and NF-κB mRNA and protein levels. GNV treatment improved EAMG rats, as shown by downregulated TLR-4 and NF-κB p65 levels ([Figure 5F--5H](#f5-medscimonit-26-e919150){ref-type="fig"}). These results suggest that GNV treatment observably inhibited TLR-4/NF-κB pathway activity in EAMG rats.

Discussion
==========

The EAMG model of a chronic autoimmune disease was induced with a synthetic rat 97\~116 peptide. First-line therapies for neurological autoimmune diseases depend on generalized immunosuppression, which is often associated with adverse effects. Therefore, the search for new and better therapies may help to enhance quality of life of MG patients. In the present study, we discovered that treatment with GVN capsules improved the holding power and depressed the Lennon scores of EAMG female Lewis rats. Further, we found that GVN treatment ameliorated the decreased RNS in EAMG rats. This study provides convincing evidence that GVN is effective in depressing the severity of disease and symptoms in EAMG rats.

Muscle weakness is mostly caused by autoantibodies specific to AChR at the NMJ in the EAMG rat model \[[@b18-medscimonit-26-e919150],[@b19-medscimonit-26-e919150]\]. Hence, depressing anti-AChR IgG secretion could be a promising therapeutic strategy for EAMG. Using the aforementioned therapeutic method, we assessed whether GVN could affect anti-AChR antibody secretion *in vivo*. Results of ELISA in serum suggested that GVN-treated EAMG rats produced significantly reduced levels of AChR-ab, and the effect was dose-dependent. *In vivo* findings indicated that treatment with GVN modulated the initiation and progression of EAMG. Further, the secretion of inflammatory cytokines and imbalance of Th1/Th17/Th2/Treg immune cells play a central role in the pathogenesis of EAMG. Th1 responses are essential in the pathogenesis of EAMG and are correlated with IFN-γ and TNF-α \[[@b20-medscimonit-26-e919150],[@b21-medscimonit-26-e919150]\]. Also, Th17 cells play a significant role in predisposing to EAMG by secreting IL-17 \[[@b20-medscimonit-26-e919150],[@b22-medscimonit-26-e919150]\]. TGF-β1, an important endogenous immunoregulator, is expressed in mammals and is involved in many pathophysiological activities. TGF-β1 suppresses B cell proliferation and downregulates IFN-γ production, suggesting an important role of TGF-β1 of EAMG \[[@b23-medscimonit-26-e919150]\]. Our results showed that GVN decreased the levels of IFN-γ, TNF-α, IL-2, IL-4, and IL-17 and increased TGF-β1 levels, indicating that GVN regulates the imbalance between Th1/Th2/Th17 cells in EAMG to limit disease progression.

A different biological effect of neuromuscular disorders on particular muscle groups was found in numerous clinical observations. Our present RNA microarray analysis of the gastrocnemius muscle with GVN treatment showed that 175 upregulated genes were significantly associated with leukocyte cell--cell adhesion and NF-kappa B signaling pathway, and 60 downregulated genes were related to muscle contraction. This finding suggests that the abnormalities of the immune system and inflammation are significant causes of the progression of MG.

To further screen out the hub genes from these up-/downregulated DEGs, we screened them through network topology calculation of PPI networks. We found 5 genes with higher degree values -- Rac2, Itgb2, Lcp2, Myl3, and Tnni1 -- in which the changes were consistent with the results of microarray analysis. Rac is a small monomeric GTPase, and possesses 3 different isoforms: Rac1, Rac2, and Rac3 \[[@b24-medscimonit-26-e919150]\]. Rac2, a homolog of Rac1 GTPase, interacts with effector proteins and mediates multiple biological events when combined with GTP \[[@b25-medscimonit-26-e919150]\]; it also is the key signal transducer in inflammatory cells and influences expression of numerous cytokines and growth factors \[[@b26-medscimonit-26-e919150]\]. Ceneri et al. demonstrated that Rac2 deletion results in a basal elevation of inactivated Rac1, and then Rac1 contributes to activation of NF-κB signaling \[[@b27-medscimonit-26-e919150]\]. However, other studies have shown that Rac2 deficiency suppresses pro-inflammatory cytokines and chemokines, as well as fibrosis-related signals in CCl4-induced acute liver injury \[[@b28-medscimonit-26-e919150]\]. Bruder et al. found that atorvastatin reduces the pro-inflammatory actions of aldosterone in vascular smooth muscle cells by inhibiting Rac1/2 \[[@b29-medscimonit-26-e919150]\]. Furthermore, RAC2 may act as a promising prognostic and diagnostic biomarker of clear cell renal cell carcinoma \[[@b30-medscimonit-26-e919150]\], osteosarcoma \[[@b31-medscimonit-26-e919150]\], and prostate cancer \[[@b32-medscimonit-26-e919150]\]. The Itgb2 gene includes 16 exons, coding for the integrin subunit β2 \[[@b33-medscimonit-26-e919150]\], and participates in leukocyte adhesion, activation, and transmigration to sites of inflammation \[[@b34-medscimonit-26-e919150]\]. The present study shows that by increasing expression of Itgb2 in the gastrocnemius muscle, adhesion and trans-endothelial migration of leukocytes is facilitated by grilled nux vomica treatment. Research suggests that the downregulation of lncRNA Itgb2-AS1 inhibits the proliferation, metastasis, and invasion of osteosarcoma \[[@b35-medscimonit-26-e919150]\] and breast cancer \[[@b36-medscimonit-26-e919150]\]. The adaptor protein SLP-76 (also known as Lcp2) is tyrosine phosphorylated by ZAP-70 and is the essential hub for recruitment of SH2 domain-containing signaling proteins \[[@b37-medscimonit-26-e919150]\]. Li et al. reported that Lcp2 plays a significant role in promoting T cell proliferation \[[@b38-medscimonit-26-e919150]\]. Additionally, a splice variant of Lcp2 leads to severe immune dysregulation \[[@b39-medscimonit-26-e919150]\]. Skeletal muscles of rats consist of 2 types -- slow-twitch (type I fiber), and fast-twitch (type II) fiber -- and Myl3 is an essential myosin light chain 3 of cardiac muscle and is expressed highly in type I skeletal muscle fibers \[[@b40-medscimonit-26-e919150]\]. Maliver et al. demonstrated that significant increases of Myl3 were correlated with myofiber degeneration \[[@b41-medscimonit-26-e919150]\]. TNNI1 is located at 1q31.3, belongs to the TnI subfamily, and encodes the slow skeletal muscle isoform of TnI (ssTnI) \[[@b42-medscimonit-26-e919150]\], which is expressed in the skeletal muscle and heart of embryos \[[@b43-medscimonit-26-e919150]\]. Moreover, ssTnI has been reported to be a sensitive and fast fiber-specific serum marker of skeletal muscle injury \[[@b44-medscimonit-26-e919150]\]. Among these, the Rac2-mediated inflammation, the leukocytes adhesion regulation of Itgb2, the Lcp2-modulated immune process, and the slow-fiber-related genes (Myl3, TNNI1), may play vital roles in the effect of GVN treatment on MG progression.

Additionally, to confirm whether the effects of GVN on the inhibition of inflammation were regulated through inactivation of the TLR-4/NF-κB pathway, the TLR-4 and NF-κB p65 protein expression levels were measured by Western blot. TLR-4, an important transmembrane protein that participates in signal transduction, belongs to the TLR family, and NF-κB is the downstream signaling molecule of TLR-4. Cordiglieri et al. demonstrated that TLR-4 is over-expressed in MG thymuses, and contributed to abnormal cell recruitment in MG thymus via CCL17 and CCL22 \[[@b45-medscimonit-26-e919150]\]. Previous studies have also demonstrated that activated NF-κB protein is transferred into the nucleus to increase pro-inflammatory cytokines TNF-α, IL-6, and IL-1 transcription expression \[[@b46-medscimonit-26-e919150]\]. These results indicate that the TLR4 and NF-κB p65 protein levels were significantly upregulated in EAMG rats, and these effects were reversed by treatment with GVN. In agreement with KEGG pathways enrichment analysis, our data also show that GVN significantly inhibits TLR-4/NF-κB signaling, which contributes to its anti-inflammatory activity in MG.

Conclusions
===========

In summary, we demonstrated that treatment with grilled nux vomica attenuated the severity of disease in EAMG rats by decreasing the production of pro-inflammatory cytokines and inhibition of TLR-4/NF-κB signaling. These findings indicate that grilled nux vomica, as well as Rac2, Itgb2, Lcp2, Myl3, and Tnni1, have potential as new treatment strategies for MG.
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![Grilled nux vomica treatment ameliorated the severity of R97-116-induced EAMG in Lewis rats. The holding power (**A**), clinical score (**B**), and decrease in of RNS (**C**) of rats in control and grilled nux vomica-treated groups (n=12 rats/group) were assessed between the after modeling and after grilled nux vomica treatment. Data are expressed as the mean±SD (\*\* *P*\<0.01, versus control group; ^\#\#^ *P*\<0.01, versus model group). RNS -- repetitive nerve stimulation.](medscimonit-26-e919150-g001){#f1-medscimonit-26-e919150}

![Grilled nux vomica regulates biochemical parameters of serum in EAMG rats. The levels of AChR-ab (**A**), IFN-γ (**B**), IL-4 (**C**), IL-17 (**D**), TNF-α (**E**), IL-2 (**F**), and TGF-β (**G**) in serum analyzed by ELISA. The results are expressed as mean±SD (n=12 rats/group), and ^\#^ *P*\<0.05; ^\#\#^ *P*\<0.01, versus model group.](medscimonit-26-e919150-g002){#f2-medscimonit-26-e919150}

![Identification of DEGs between grilled nux vomica-treated group (225 mg/kg) and model group, and bioinformatics analysis of up-/downregulated DEGs. (**A**) Volcano plots of DEGs. There were 175 genes upregulated and 60 downregulated genes in gastrocnemius muscle. Hierarchical clusters of the DEGs in the treated groups and model group (**B**). Biological processes (**C**) and KEGG pathways enrichment analyses (**D**) of upregulated DEGs. Biological processes (**E**) and KEGG pathways enrichment analyses (**F**) of downregulated DEGs. DEGs -- differently expressed genes.](medscimonit-26-e919150-g003){#f3-medscimonit-26-e919150}

![Protein--protein interaction (PPI) network for the DEGs. PPI network of upregulated DEGs (**A**). PPI network of downregulated DEGs (**B**). Red nodes, upregulated genes; green nodes, downregulated genes; (Rac2, Lcp2, and Itgb2) as well as (Myl3 and Tnni1) are the hub genes in upregulated and downregulated network with a higher degree value.](medscimonit-26-e919150-g004){#f4-medscimonit-26-e919150}

![Grilled Nux Vomica regulates hub genes and the TLR-4/NF-κB pathway in the gastrocnemius muscle of EAMG rats. The mRNA expression level of Rac2 (**A**), Itgb2 (**B**), Lcp2 (**C**), Myl3 (**D**), and Tnni1 (**E**) was measured by quantitative real-time PCR (q-PCR). Additionally, the protein expression level of Rac2, Itgb2, Lcp2, Myl3, Tnni1, TLR-4, and NF-κB p65 (**F**) was determined by Western blot. Further, the transcriptional expression level of TLR-4 (**G**) and NF-κB (**H**) was assessed with q-PCR. Data are presented as mean±SD, and ^\#^ *P*\<0.05; ^\#\#^ *P*\<0.01, versus model group.](medscimonit-26-e919150-g005){#f5-medscimonit-26-e919150}

###### 

The primers for RT-PCR.

  Gene    Forward primer (5′-3′)   Reverse primer (5′-3′)
  ------- ------------------------ ------------------------
  Rac2    TACACCACCAATGCCTTCCC     GTGATGGGAGCCAGCTTCTT
  Itgb2   GTTTCAGACAGAGGTCGGCA     TGCTCCTGGATACACTCCGA
  Lcp2    ATGGCGCTCGGTTTTTGAAC     CAGGATATCGTGGAACCGGG
  Myl3    AATCCTACCCAGGCAGAGGT     TTGCCCTCCTTGTCGAAGAC
  Tnni1   AGGCTGAGAAGGTGCGTTAC     GGAGCTCTCGGCATAAGTCC
  TLR-4   TGTATCGGTGGTCAGTGTGC     TCCCACTCGAGGTAGGTGTT
  NF-κB   GGATAGCACTGGCAGCTTCA     TCCTCCGAAGCTGGACAAAC
  GADPH   GCGGGAGCGGATCCTAATA      TGGTGCATCCATGGGCTAC

Rac2-- Rac family small GTPase 2; Itgb2 -- integrin subunit beta 2; Lcp2-- lymphocyte cytosolic protein 2; Myl3-- myosin light chain 3; Tnni1-- troponin I1, slow skeletal type.

###### 

Comparison of average weight among the groups after grilled nux vomica treatment.

  Groups              Average weight (after nux vomica treatment) (g)                      n                                                                                                                                                                                                               
  ------------------- -------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------- ---
  Control             226.8±4.2                                                            237.7±4.6[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   247.5±7.0[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   266.1±6.8[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}    8
  Model               187.3±2.5[\#\#](#tfn3-medscimonit-26-e919150){ref-type="table-fn"}   182.2±4.0                                                            174.2±4.4                                                            157.4±5.9                                                             8
  Low-dose group      188.0±4.5[\#\#](#tfn3-medscimonit-26-e919150){ref-type="table-fn"}   197.8±6.3[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   202.1±8.1[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   216.4±6.4[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}    8
  Middle-dose group   188.4±8.2[\#\#](#tfn3-medscimonit-26-e919150){ref-type="table-fn"}   200.9±5.5[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   217.6±5.7[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   233.3±5.4[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}    8
  High-dose group     190.9±6.4[\#\#](#tfn3-medscimonit-26-e919150){ref-type="table-fn"}   212.9±4.3[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   225.0±3.7[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   244.4±5.7[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}    8
  Prednisone group    185.7±2.9[\#\#](#tfn3-medscimonit-26-e919150){ref-type="table-fn"}   191.2±5.2[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   220.4±8.4[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   249.3±11.1[\*\*](#tfn4-medscimonit-26-e919150){ref-type="table-fn"}   8

The results are expressed as mean±SD (n=8 rats/group). Comparison of average weight in the control, model, low-, middle-, and high-dose groups after grilled nux vomica treatment, respectively,

*P*\<0.01; The model, high-, middle- and low-dose groups *vs.* control group;

*P*\<0.01*;* The control, high-, middle- and, low-dose groups *vs.* model group.
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